List view / Grid view


Application note: GABAA Receptors

11 December 2018 | By

SB Drug Discovery shows the validation of fluorescence and automated electrophysiology assays designed to assess agonists, antagonists and allosteric modulators of these receptors, culminating in a high-throughput electrophysiology assay suited to assessing multiple GABAA receptor subtypes on a single assay plate.

Application note: Production of human induced pluripotent stem cell-derived cortical neurospheres in the DASbox® Mini Bioreactor System

29 November 2018 | By

There is substantial interest in the scientific community in using human induced pluripotent stem cell (hiPSC)-derived neural cells to study basic mechanisms of brain development, neuronal function, and drug-induced effects. In vitro-generated brain organoids are promising models, because they show a remarkable degree of maturation and can be kept in…

Application note: Sensitive fluorometric quantification of DNA in microplate format

29 November 2018 | By

This technical note demonstrates the feasibility of using the Thermo Scientific™Fluoroskan™ or Fluoroskan FL instruments with the Invitrogen™ Quant-iT™ dsDNAhigh-sensitivity assays. Sensitive and specific quantification of double-stranded DNA is carried out in microplate format. This is part of a series of technical notes aiming to help customers choose the best…

Application note: Enabling single-software multiple attribute methodology (MAM) for the assessment of biopharmaceutical product quality attributes

29 November 2018 | By , ,

Development and production of biopharmaceuticals is complex. Even minor impurities, or changes in attributes such as glycosylation or charge heterogeneity, can have a profound impact on the safety and efficacy of the final product. Traditionally, multiple analytical techniques have been required to assess the full range of biopharmaceutical product attributes.…

Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software

29 November 2018 | By

Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.

Application note: A novel solution to expedite antibody discovery

29 November 2018 | By

With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.